IMAB 027-vcMMAE
Alternative Names: IMAB 027-monomethyl auristatin E; IMAB 027/monomethyl auristatin E; IMAB027–vcMMAELatest Information Update: 28 May 2022
At a glance
- Originator Ganymed Pharmaceuticals
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
- 21 Apr 2018 Preclinical trials in Cancer in Germany (Parenteral) before April 2018
- 21 Apr 2018 Pharmacodynamics and adverse events data from a preclinical study in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)